Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.
Dorff T, Horvath LG, Autio K, Bernard-Tessier A, Rettig MB, Machiels JP, Bilen MA, Lolkema MP, Adra N, Rottey S, Greil R, Matsubara N, Tan DSW, Wong A, Uemura H, Lemech C, Meran J, Yu Y, Minocha M, McComb M, Penny HL, Gupta V, Hu X, Jurida G, Kouros-Mehr H, Janát-Amsbury MM, Eggert T, Tran B. Dorff T, et al. Among authors: rettig mb. Clin Cancer Res. 2024 Apr 15;30(8):1488-1500. doi: 10.1158/1078-0432.CCR-23-2978. Clin Cancer Res. 2024. PMID: 38300720 Clinical Trial.
Androgen Receptor Modulation Optimized for Response (ARMOR) Phase I and II Studies: Galeterone for the Treatment of Castration-Resistant Prostate Cancer.
Montgomery B, Eisenberger MA, Rettig MB, Chu F, Pili R, Stephenson JJ, Vogelzang NJ, Koletsky AJ, Nordquist LT, Edenfield WJ, Mamlouk K, Ferrante KJ, Taplin ME. Montgomery B, et al. Among authors: rettig mb. Clin Cancer Res. 2016 Mar 15;22(6):1356-63. doi: 10.1158/1078-0432.CCR-15-1432. Epub 2015 Nov 2. Clin Cancer Res. 2016. PMID: 26527750 Free article. Clinical Trial.
Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Guan X, Sun D, Lu E, Urrutia JA, Reiter RE, Rettig M, Evans CP, Lara P Jr, Gleave M, Beer TM, Thomas GV, Huang J, Aggarwal RR, Quigley DA, Foye A, Chen WS, Youngren J, Weinstein AS, Stuart JM, Feng FY, Small EJ, Xia Z, Alumkal JJ. Guan X, et al. Clin Cancer Res. 2020 Sep 1;26(17):4616-4624. doi: 10.1158/1078-0432.CCR-19-2303. Epub 2020 Jul 29. Clin Cancer Res. 2020. PMID: 32727885 Free PMC article.
Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.
Abida W, Hahn AW, Shore N, Agarwal N, Sieber P, Smith MR, Dorff T, Monk P, Rettig M, Patel R, Page A, Duff M, Xu R, Wang J, Barkund S, Pankov A, Wang A, Junttila MR, Multani PS, Daemen A, Chow Maneval E, Logothetis CJ, Morris MJ. Abida W, et al. Clin Cancer Res. 2024 Mar 15;30(6):1111-1120. doi: 10.1158/1078-0432.CCR-23-3508. Clin Cancer Res. 2024. PMID: 38226958 Free PMC article. Clinical Trial.
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway).
Hussain M, Kocherginsky M, Agarwal N, Adra N, Zhang J, Paller CJ, Picus J, Reichert ZR, Szmulewitz RZ, Tagawa ST, Kuzel TM, Bazzi LA, Daignault-Newton S, Whang YE, Dreicer R, Stephenson RD, Rettig MB, Shevrin D, Gerke T, Chinnaiyan AM, Antonarakis ES. Hussain M, et al. Among authors: rettig mb. Clin Cancer Res. 2024 Oct 1;30(19):4318-4328. doi: 10.1158/1078-0432.CCR-24-1402. Clin Cancer Res. 2024. PMID: 39115414 Clinical Trial.
Implementing evidence-based strategies for men with biochemically recurrent and advanced prostate cancer: Consensus recommendations from the US Prostate Cancer Conference 2024.
Bryce AH, Agarwal N, Beltran H, Hussain MH, Sartor O, Shore N, Antonarakis ES, Armstrong AJ, Calais J, Carducci MA, Dorff TB, Efstathiou JA, Gleave M, Gomella LG, Higano C, Hope TA, Iagaru A, Morgans AK, Morris DS, Morris MJ, Petrylak DP, Reiter RE, Rettig MB, Ryan CJ, Sellinger SB, Spratt DE, Srinivas S, Tagawa ST, Taplin ME, Yu EY, Zhang T, McKay RR, Koo PJ, Crawford ED. Bryce AH, et al. Among authors: rettig mb. Cancer. 2025 Jan 1;131(1):e35612. doi: 10.1002/cncr.35612. Epub 2024 Dec 1. Cancer. 2025. PMID: 39616467 Free PMC article.
PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging.
Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, Gafita A, Thin P, Nickols NG, Kishan AU, Rettig MB, Reiter RE, Czernin J, Calais J. Holzgreve A, et al. Among authors: rettig mb. JAMA Netw Open. 2025 Jan 2;8(1):e2452971. doi: 10.1001/jamanetworkopen.2024.52971. JAMA Netw Open. 2025. PMID: 39752157 Free PMC article.
161 results